Sign In
Buy CMPX
$2.10
+0.0200 (+0.96%)
At Close: Jun 03, 2026
Tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel demonstrated a highly statistically significant improvement versus paclitaxel alone in the key secondary endpoint of medi
BOSTON, April 24, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to
Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Rating of “Moderate Buy” from Brokerages
03:20am, Sunday, 12'th Apr 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the fourteen ratings firms that are covering the company, MarketBeat reports. On
Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Average Recommendation of “Moderate Buy” by Brokerages
03:12am, Wednesday, 18'th Mar 2026
Compass Therapeutics, Inc. (NASDAQ: CMPX - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the fifteen brokerages that are covering the firm, MarketBeat.com report
Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update
07:30am, Thursday, 05'th Mar 2026
In the Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer, the prespecified event threshold of 80% overall survival (OS) events was re
Investment Advisor Bets Big on CMPX Stock, Adds 2.5 Million Shares, According to Latest SEC Filing
12:29pm, Monday, 02'nd Mar 2026
Purchased 2,532,419 shares in CMPX; position value was $13,599,090 as of December 31, 2025 Quarter-end value of the CMPX stake was $13,599,090, resulting from the new position initiated during the qua
Is Compass Therapeutics, Inc. (CMPX) Outperforming Other Medical Stocks This Year?
10:40am, Tuesday, 17'th Feb 2026
Here is how Compass Therapeutics, Inc. (CMPX) and Ekso Bionics (EKSO) have performed compared to their sector so far this year.
Wall Street Analysts See an 113.73% Upside in Compass Therapeutics, Inc. (CMPX): Can the Stock Really Move This High?
10:56am, Tuesday, 27'th Jan 2026
The average of price targets set by Wall Street analysts indicates a potential upside of 113.7% in Compass Therapeutics, Inc. (CMPX). While the effectiveness of this highly sought-after metric is ques
Compass Therapeutics: Exciting Clinical Updates Inbound For 2026
11:25am, Tuesday, 20'th Jan 2026
Compass Therapeutics remains a 'Buy,' but valuation above $1B stretches risk/reward as it awaits pivotal clinical catalysts. Tovecimig's early data in biliary tract and refractory colorectal cancers s
Compass Therapeutics, Inc. (CMPX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
01:26pm, Wednesday, 14'th Jan 2026
Compass Therapeutics, Inc. (CMPX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Compass Therapeutics Provides Corporate Update
08:00am, Tuesday, 06'th Jan 2026
The analyses of progression-free survival (PFS) and overall survival (OS) remain on track for late Q1 2026 in the ongoing Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody)
Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Monday, 05'th Jan 2026
BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to
Compass Therapeutics Announces Key Leadership Appointments
08:00am, Monday, 05'th Jan 2026
BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to
Compass Therapeutics (NASDAQ:CMPX) Shares Up 4.5% – What’s Next?
01:32am, Wednesday, 31'st Dec 2025
Compass Therapeutics, Inc. (NASDAQ: CMPX - Get Free Report) shares rose 4.5% during mid-day trading on Tuesday. The stock traded as high as $5.39 and last traded at $5.38. Approximately 1,662,732 shar
Are Medical Stocks Lagging Compass Therapeutics, Inc. (CMPX) This Year?
10:41am, Friday, 19'th Dec 2025
Here is how Compass Therapeutics, Inc. (CMPX) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.
